Stereotaxis, Inc. Hits New 52-Week High of $3.58, Marking Key Milestone

Stereotaxis, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 3.58 on October 8, 2025. This achievement marks a notable increase from its 52-week low of USD 1.54, reflecting a substantial upward movement in the stock's performance over the past year.
Despite this recent high, Stereotaxis has experienced a 1-year performance decline of 0.28%, contrasting sharply with the S&P 500's impressive gain of 17.88% during the same period. The company's market capitalization stands at USD 262 million, indicating its microcap status within the industry.

Financial metrics reveal that Stereotaxis is currently loss-making, with a negative return on equity of 345.88% and a debt-to-equity ratio of -0.94. The stock does not offer a dividend yield, and its price-to-book ratio is notably high at 38.85. As Stereotaxis continues to navigate the competitive landscape of pharmaceuticals and biotechnology, this recent price milestone highlights its current market position.